Who is sponsoring NCT03366415?

NCT03366415 is sponsored by Chaosu Hu.

What drugs are being tested in NCT03366415?

Interventions in NCT03366415: gemcitabine and cisplatin (Induction and adjuvant chemotherapy), IMRT, gemcitabine and cisplatin (Induction chemotherapy), IMRT and concurrent cisplatin.

What condition does NCT03366415 study?

NCT03366415 studies Nasopharyngeal Carcinoma.

Is NCT03366415 still recruiting?

NCT03366415 is currently status unknown. Last updated 4 March 2022.

Last reviewed 2022-03-04 · How we verify

NCT03366415

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC

Status unknown Phase 3 Last updated 4 March 2022

What this trial tests

Phase 3 trial testing gemcitabine and cisplatin (Induction and adjuvant chemotherapy) in Nasopharyngeal Carcinoma in 420 participants. Status unknown.

Timeline

1 January 2018

Primary endpoint
30 September 2024

30 December 2024

Quick facts

Lead sponsor	Chaosu Hu
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	420
Start date	1 January 2018
Primary completion	30 September 2024
Estimated completion	30 December 2024
Sites	1 location across China

Drugs / interventions tested

gemcitabine and cisplatin (Induction and adjuvant chemotherapy) — full drug profile →
IMRT
gemcitabine and cisplatin (Induction chemotherapy) — full drug profile →
IMRT and concurrent cisplatin

Conditions studied

Nasopharyngeal Carcinoma — all drugs for Nasopharyngeal Carcinoma →

Sponsor

Chaosu Hu — full company profile →

Who can join

Adults 18 to 65, any sex, with Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare the efficacy and safety of sequential chemoradiotherapy (induction chemotherapy + intensity-modulated radiotherapy +adjuvant chemotherapy) with induction chemotherapy plus concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC), in order to confirm the value of sequential chemoradiotherapy in NPC patients.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma.
Peng L, Liu JQ, Chen YP, Ma J. · · 2019 · cited 17× · PMID 31112398 · DOI 10.1259/bjr.20181031
Comparing Long-Term Survival and Late Toxicities of Different Sequential Chemotherapy Regimens with Intensity-Modulated Radiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma.
Wu M, Ou D, Hu C, He X. · · 2020 · cited 7× · PMID 32361309 · DOI 10.1016/j.tranon.2020.100765
Sequential vs Induction Plus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
Xue F, Ou D, Xie C, Lin S, et al · · 2025 · cited 4× · PMID 40705321 · DOI 10.1001/jamaoncol.2025.2191
Prognostic value of lymph node-to-primary tumor ratio of PET standardized uptake value for nasopharyngeal carcinoma: a recursive partitioning risk stratification analysis.
Kong FF, Pan GS, Ni MS, Du CR, et al · · 2024 · cited 2× · PMID 38379851 · DOI 10.1177/17588359241233235

Verify or expand the search:

Other recruiting trials for Nasopharyngeal Carcinoma

Currently open trials in the same condition.

NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
NCT07328854 — 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06912711 — TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma · Phase 2 · recruiting
NCT07000643 — Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06682442 — Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma · NA · recruiting

Other Chaosu Hu trials

Trials by the same sponsor.

NCT04158518 — De-escalation Protocols in Locoregionally Advanced Nasopharyngeal Carcinoma · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03366415 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chaosu Hu
Last refreshed: 4 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03366415.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing